Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Clin Pharmacol Ther. 2018 Apr;103(4):574-581. doi: 10.1002/cpt.1004. Epub 2018 Feb 2.


The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticonvulsants / pharmacology
  • Carbamazepine / pharmacology*
  • Drug-Related Side Effects and Adverse Reactions* / genetics
  • Drug-Related Side Effects and Adverse Reactions* / prevention & control
  • HLA-B Antigens / genetics*
  • Humans
  • Oxcarbazepine / pharmacology*
  • Pharmacogenetics / methods
  • Pharmacogenetics / standards


  • Anticonvulsants
  • HLA-B Antigens
  • Carbamazepine
  • Oxcarbazepine